Clinical Trials Data Document Packaging 
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A Visit www.floragrowth.ca
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off. Originally Published At Microdose.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 28, 2021
Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. Position duties: Electronic document preparation and submission of electronic common technical document (eCTD) submissions to regulatory agencies.
Cannabis Law Report
FEBRUARY 5, 2022
Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities.
Cannabis Law Report
DECEMBER 15, 2021
Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities.
Cannabis Law Report
AUGUST 23, 2021
At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials.
NORML
SEPTEMBER 20, 2019
Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials. Can you explain how it’s prepared for shipping at the University of Mississippi and how it comes packaged? Photo courtesy MAPS.
Expert insights. Personalized for you.
52 
Let's personalize your content